These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36127550)

  • 21. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
    Vancheeswaran R; Magoulas T; Efrat G; Wheeler-Jones C; Olsen I; Penny R; Black CM
    J Rheumatol; 1994 Oct; 21(10):1838-44. PubMed ID: 7837147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis.
    Fukayama M; Yoshizaki A; Fukasawa T; Ebata S; Kuzumi A; Yoshizaki-Ogawa A; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Nov; 47(11):1287-1292. PubMed ID: 32686186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Takahashi T; Akamata K; Aozasa N; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Rheumatology (Oxford); 2013 May; 52(5):790-9. PubMed ID: 23287360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis.
    Henderson J; Duffy L; Stratton R; Ford D; O'Reilly S
    J Cell Mol Med; 2020 Dec; 24(23):14026-14038. PubMed ID: 33140521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis.
    Wohlfahrt T; Usherenko S; Englbrecht M; Dees C; Weber S; Beyer C; Gelse K; Distler O; Schett G; Distler JH; Ramming A
    Ann Rheum Dis; 2016 Mar; 75(3):623-6. PubMed ID: 26338035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
    Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
    J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
    Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
    Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis.
    Campochiaro C; Lytton S; Nihtyanova S; Fuchs D; Ong VH; Denton CP
    Clin Immunol; 2019 Feb; 199():18-24. PubMed ID: 30771500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
    Fuschiotti P; Medsger TA; Morel PA
    Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-16 expression is increased in the skin and sera of patients with systemic sclerosis.
    Kawabata K; Makino T; Makino K; Kajihara I; Fukushima S; Ihn H
    Rheumatology (Oxford); 2020 Mar; 59(3):519-523. PubMed ID: 31377804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global hypomethylation pattern in systemic sclerosis: An application for absolute quantification of epigenetic DNA modification products by 2D-UPLC-MS/MS.
    Dal-Bekar NE; Siomek-Gorecka A; Gackowski D; Köken-Avşar A; Yarkan-Tuğsal H; Birlik M; İşlekel H
    Clin Immunol; 2022 Jun; 239():108997. PubMed ID: 35398518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum level of circulating syndecan-1: A possible association with proliferative vasculopathy in systemic sclerosis.
    Wu CY; Asano Y; Taniguchi T; Sato S; Yu HS
    J Dermatol; 2016 Jan; 43(1):63-6. PubMed ID: 26076711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.
    Almeida I; Silva SV; Fonseca AR; Silva I; Vasconcelos C; Lima M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):347-69. PubMed ID: 26445774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum.
    Cossu M; van Bon L; Preti C; Rossato M; Beretta L; Radstake TRDJ
    Arthritis Rheumatol; 2017 Dec; 69(12):2359-2369. PubMed ID: 28859262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis.
    Stochmal A; Czuwara J; Zaremba M; Rudnicka L
    Arch Dermatol Res; 2020 Aug; 312(6):453-458. PubMed ID: 31667578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis.
    Makino K; Jinnin M; Makino T; Kajihara I; Fukushima S; Inoue Y; Ihn H
    Biosci Trends; 2014 Jun; 8(3):144-8. PubMed ID: 25030848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.
    Wagner A; Köhm M; Nordin A; Svenungsson E; Pfeilschifter JM; Radeke HH
    Scand J Immunol; 2015 Sep; 82(3):269-74. PubMed ID: 26095613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.